Acne Vulgaris Treatment PrARAZLO(TM) Now Accessible via BC PharmaCare

Bausch Health Companies Inc. has announced that PrARAZLO(TM) (tazarotene lotion, 0.045% w/w), a topical prescription treatment for acne vulgaris, is now available to British Columbia residents through the BC PharmaCare public drug plan. This makes PrARAZLOTM accessible to patients on all public drug plans across Canada. Health Canada has approved ARAZLO as the sole tazarotene lotion treatment for acne vulgaris for patients aged 10 and older. The formulation incorporates PRISMATREXTM technology, tailored to enhance skin hydration and reduce dryness, a common side effect of retinoids.

The availability of ARAZLO through BC PharmaCare is hailed by healthcare professionals and advocacy groups, highlighting its potential to improve patient tolerance and treatment outcomes. With approximately 5.6 million Canadians affected by acne, the diversity in treatment options is key to managing the condition effectively. ARAZLO’s approval and distribution underscore Bausch Health's commitment to addressing Canadians' dermatological needs and expanding access to innovative treatments.